Company intelligence / Profile preview

The Blooms

San Diego, California, United Statesbloomsbythebox.com ↗

Ownership: Private
Development stage: Other

Overview

Bloom Science’s lead program, BL‑001, is a live biotherapeutic product reverse engineered to replicate the clinical efficacy of the ketogenic diet. In a Phase 1 trial, BL‑001 demonstrated statistically significant and durable weight loss in overweight individuals. The company plans to advance BL‑001 into Phase 2 trials for both obesity and Dravet syndrome.

Therapeutic areas: EndocrinologyNeurology
Modalities: Live biotherapeutic product therapyMicrobial therapySynthetic biology-based therapy
Industry: Biotech

Partnerships

Leaps by Bayer / Bayer AG investment armALS Investment Fund

Beyond the preview

Go deeper on The Blooms.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Blooms.

Explore the full profile